{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:55:18Z","timestamp":1776254118936,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04593-1","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T06:16:04Z","timestamp":1772950564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The combination therapy with venetoclax in therapeutic strategy of acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"17","author":[{"given":"Mobina Nakhaei","family":"Shamahmood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Javad","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abolfazl","family":"Miri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Mezginejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"issue":"6","key":"4593_CR1","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577\u2013e577.","journal-title":"Blood Cancer J"},{"issue":"9","key":"4593_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10091926","volume":"10","author":"H Inaba","year":"2021","unstructured":"Inaba H, Pui C-H. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J Clin Med. 2021;10(9):1926.","journal-title":"J Clin Med"},{"key":"4593_CR3","volume-title":"Mayo Clinic Proceedings","author":"S Paul","year":"2016","unstructured":"Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. In: Mayo Clinic Proceedings. Elsevier; 2016."},{"issue":"15","key":"4593_CR4","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/cncr.29383","volume":"121","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, et al. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015;121(15):2517\u201328.","journal-title":"Cancer"},{"issue":"16","key":"4593_CR5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541\u201352.","journal-title":"N Engl J Med"},{"issue":"9881","key":"4593_CR6","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","volume":"381","author":"H Inaba","year":"2013","unstructured":"Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381(9881):1943\u201355.","journal-title":"Lancet"},{"issue":"4","key":"4593_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41571-018-0136-6","volume":"16","author":"C-H Pui","year":"2019","unstructured":"Pui C-H, Nichols KE, Yang JJ. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol. 2019;16(4):227\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"4593_CR8","first-page":"83","volume":"64","author":"E Ward","year":"2014","unstructured":"Ward E, et al. Childhood and adolescent cancer statistics, 2014. CA: a cancer journal for clinicians. 2014;64(2):83\u2013103.","journal-title":"CA: a cancer journal for clinicians"},{"issue":"9","key":"4593_CR9","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58(9):2026\u201339.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"4593_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113353","volume":"12","author":"VS Lin","year":"2020","unstructured":"Lin VS, et al. Bh3 mimetics for the treatment of b-cell malignancies\u2014insights and lessons from the clinic. Cancers. 2020;12(11):3353.","journal-title":"Cancers"},{"issue":"3","key":"4593_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/bjh.14684","volume":"178","author":"M Vogler","year":"2017","unstructured":"Vogler M, Walter HS, Dyer MJ. Targeting anti-apoptotic BCL 2 family proteins in haematological malignancies\u2013from pathogenesis to treatment. Br J Haematol. 2017;178(3):364\u201379.","journal-title":"Br J Haematol"},{"issue":"6","key":"4593_CR12","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/10428194.2020.1719098","volume":"61","author":"C Lachowiez","year":"2020","unstructured":"Lachowiez C, DiNardo CD, Konopleva M. Venetoclax in acute myeloid leukemia\u2013current and future directions. Leuk Lymphoma. 2020;61(6):1313\u201322.","journal-title":"Leuk Lymphoma"},{"key":"4593_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.exphem.2018.02.002","volume":"61","author":"J Mihalyova","year":"2018","unstructured":"Mihalyova J, et al. Venetoclax: a new wave in hematooncology. Exp Hematol. 2018;61:10\u201325.","journal-title":"Exp Hematol"},{"issue":"18","key":"4593_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810957","volume":"23","author":"S Aumann","year":"2022","unstructured":"Aumann S, et al. The emerging role of venetoclax-based treatments in acute lymphoblastic leukemia. Int J Mol Sci. 2022;23(18):10957.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"4593_CR15","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.clml.2021.12.005","volume":"22","author":"MR Luskin","year":"2022","unstructured":"Luskin MR. SOHO state of the art updates and next questions: mini-hyper-CVD combinations for older adults: results of recent trials and a glimpse into the future. Clin Lymphoma Myeloma Leuk. 2022;22(7):436\u201341.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4593_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-3-319-91439-8_11","volume-title":"Small Molecules in Hematology","author":"A Scheffold","year":"2018","unstructured":"Scheffold A, Jebaraj BMC, Stilgenbauer S. Venetoclax: targeting BCL2 in hematological cancers. In: Small Molecules in Hematology. 2018. p. 215\u201342."},{"issue":"1","key":"4593_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2237790","volume":"28","author":"J-Y Zou","year":"2023","unstructured":"Zou J-Y, et al. Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias. Hematology. 2023;28(1):2237790.","journal-title":"Hematology"},{"issue":"6","key":"4593_CR18","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440\u201353.","journal-title":"Cancer Discov"},{"key":"4593_CR19","first-page":"159","volume-title":"Small Molecules in Oncology","author":"A M\u00fcller","year":"2009","unstructured":"M\u00fcller A, Florek M. 5-azacytidine\/Azacitidine. In: Small Molecules in Oncology. 2009. p. 159\u201370."},{"key":"4593_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-3-642-54490-3_19","volume-title":"Small Molecules in Oncology","author":"AM M\u00fcller","year":"2014","unstructured":"M\u00fcller AM, Florek M. 5-Azacytidine\/5-Azacitidine. In: Small Molecules in Oncology. 2014. p. 299\u2013324."},{"key":"4593_CR21","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2023-179733","volume":"142","author":"H-Y Cao","year":"2023","unstructured":"Cao H-Y, et al. Venetoclax combined with Azacitidine was effective and safe for Relapsed\/Refractory T-Cell acute lymphoblastic Leukemia\/Lymphoblastic lymphoma: preliminary results of a phase 2, multicenter trial. Blood. 2023;142:1501.","journal-title":"Blood"},{"issue":"2","key":"4593_CR22","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1097\/HS9.0000000000000675","volume":"6","author":"K Laribi","year":"2022","unstructured":"Laribi K, et al. Azacytidine and venetoclax in relapsed and refractory patients with angioimmunoblastic T-cell lymphoma. HemaSphere. 2022;6(2):e675.","journal-title":"HemaSphere"},{"issue":"13","key":"4593_CR23","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1080\/10428194.2021.1957876","volume":"62","author":"C-L Wan","year":"2021","unstructured":"Wan C-L, et al. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series. Leuk Lymphoma. 2021;62(13):3300\u20133.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"4593_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1365-3148.2011.01129.x","volume":"22","author":"B Cruz","year":"2012","unstructured":"Cruz B, et al. RHD alleles in Brazilian blood donors with weak D or D-negative phenotypes. Transfus Med. 2012;22(2):84\u20139.","journal-title":"Transfus Med"},{"issue":"1","key":"4593_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2344998","volume":"29","author":"Z Hao","year":"2024","unstructured":"Hao Z, et al. Combination of venetoclax and azacitidine in relapsed\/refractory acute B-cell lymphoblastic leukemia: a case series from a single center. Hematology. 2024;29(1):2344998.","journal-title":"Hematology"},{"key":"4593_CR26","doi-asserted-by":"publisher","first-page":"S196","DOI":"10.1016\/S2152-2650(22)01188-0","volume":"22","author":"MA Hassan","year":"2022","unstructured":"Hassan MA, et al. ALL-220 azacitidine in combination with Venetoclax maintenance post allogeneic hematopoietic cell transplantation in T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2022;22:S196\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"4593_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","volume":"136","author":"D Nagorsen","year":"2012","unstructured":"Nagorsen D, et al. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136(3):334\u201342.","journal-title":"Pharmacol Ther"},{"issue":"18","key":"4593_CR28","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka D, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21(18):4035\u20139.","journal-title":"Clin Cancer Res"},{"key":"4593_CR29","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2019-127296","volume":"134","author":"G Campos-Cabrera","year":"2019","unstructured":"Campos-Cabrera G, et al. Blinatumomab and venetoclax for minimal residual disease relapse in acute lymphoblastic leukemia. Blood. 2019;134:5128.","journal-title":"Blood"},{"key":"4593_CR30","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1182\/blood-2023-180520","volume":"142","author":"X Wu","year":"2023","unstructured":"Wu X, et al. Treatment with blinatumomab in combination with venetoclax for mixed phenotype acute leukemia. Blood. 2023;142:5890.","journal-title":"Blood"},{"key":"4593_CR31","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1182\/blood-2023-173937","volume":"142","author":"L Fransecky","year":"2023","unstructured":"Fransecky L, et al. Venetoclax and blinatumomab for adult patients with relapsed\/refractory or MRD positive Ph-negative B-precursor ALL: first results of the GMALL-Bliven trial. Blood. 2023;142:1502.","journal-title":"Blood"},{"issue":"2","key":"4593_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","volume":"58","author":"CRC Tan","year":"2019","unstructured":"Tan CRC, et al. Clinical pharmacokinetics and pharmacodynamics of bortezomib. Clin Pharmacokinet. 2019;58(2):157\u201368.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4593_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.tmrv.2021.06.002","volume":"35","author":"K Ejaz","year":"2021","unstructured":"Ejaz K, et al. Daratumumab: beyond multiple myeloma. Transfus Med Rev. 2021;35(3):36\u201343.","journal-title":"Transfus Med Rev"},{"issue":"4","key":"4593_CR34","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1007\/s12325-021-01948-8","volume":"39","author":"V Santini","year":"2022","unstructured":"Santini V, et al. The clinical value of decitabine monotherapy in patients with acute myeloid leukemia. Adv Ther. 2022;39(4):1474\u201388.","journal-title":"Adv Ther"},{"issue":"3","key":"4593_CR35","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.hemonc.2019.10.002","volume":"14","author":"N Farhadfar","year":"2021","unstructured":"Farhadfar N, et al. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature. Hematol Oncol Stem Cell Ther. 2021;14(3):246\u201351.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"4593_CR36","volume":"2018","author":"LT Rahmat","year":"2018","unstructured":"Rahmat LT, et al. Venetoclax in combination with decitabine for relapsed T-cell acute lymphoblastic leukemia after allogeneic hematopoietic cell transplant. Case Rep Hematol. 2018;2018:6092646.","journal-title":"Case Rep Hematol"},{"key":"4593_CR37","volume":"2020","author":"H Klocke","year":"2020","unstructured":"Klocke H, et al. Venetoclax and decitabine for T\/myeloid mixed-phenotype acute leukemia not otherwise specified (MPAL NOS). Case Rep Hematol. 2020;2020:8811673.","journal-title":"Case Rep Hematol"},{"key":"4593_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-015-0224-3","volume":"8","author":"S Cang","year":"2015","unstructured":"Cang S, et al. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol. 2015;8:129.","journal-title":"J Hematol Oncol"},{"issue":"26","key":"4593_CR39","doi-asserted-by":"publisher","first-page":"6200","DOI":"10.12998\/wjcc.v11.i26.6200","volume":"11","author":"S Park","year":"2023","unstructured":"Park S, et al. T\/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: a case report. World J Clin Cases. 2023;11(26):6200\u20135.","journal-title":"World J Clin Cases"},{"key":"4593_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","volume":"107","author":"R Roskoski","year":"2016","unstructured":"Roskoski R. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacol Res. 2016;107:249\u201375.","journal-title":"Pharmacol Res"},{"issue":"9","key":"4593_CR41","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1002\/cam4.2324","volume":"8","author":"H Zhao","year":"2019","unstructured":"Zhao H, et al. Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway. Cancer Med. 2019;8(9):4348\u201358.","journal-title":"Cancer Med"},{"key":"4593_CR42","first-page":"133","volume":"212","author":"A Charalambous","year":"2018","unstructured":"Charalambous A, Schwarzbich MA, Witzens-Harig M. Ibrutinib Recent Results. Cancer Res. 2018;212:133\u201368.","journal-title":"Cancer Res"},{"key":"4593_CR43","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1182\/blood-2019-131288","volume":"134","author":"CA Eide","year":"2019","unstructured":"Eide CA, et al. Simultaneous kinase Inhibition with ibrutinib and BCL2 Inhibition with venetoclax as a therapeutic strategy for acute lymphoblastic leukemia. Blood. 2019;134:3950.","journal-title":"Blood"},{"key":"4593_CR44","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8325","author":"H Lalic","year":"2022","unstructured":"Lalic H, Aurer I, Batinic D, Visnjic D, Smoljo T, Babic A. Bendamustine: a review of pharmacology, clinical use and immunological effects (Review). Oncol Rep. 2022. https:\/\/doi.org\/10.3892\/or.2022.8325.","journal-title":"Oncol Rep"},{"issue":"4","key":"4593_CR45","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.21873\/invivo.13624","volume":"38","author":"HDT Nguyen","year":"2024","unstructured":"Nguyen HDT, Le TM, Lee D, Cho HJ, Lee J, Sohn SK, et al. Synergistic effect of venetoclax and Bendamustine in early T-cell precursor acute lymphoblastic leukemia. Vivo. 2024;38(4):1740\u20139.","journal-title":"Vivo"},{"issue":"1","key":"4593_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/HAB-180348","volume":"27","author":"A Mukherjee","year":"2019","unstructured":"Mukherjee A, et al. Antibody drug conjugates: Progress, pitfalls, and promises. Hum Antib. 2019;27(1):53\u201362.","journal-title":"Hum Antib"},{"issue":"20","key":"4593_CR47","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","volume":"17","author":"AD Ricart","year":"2011","unstructured":"Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011;17(20):6417\u201327.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4593_CR48","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-021-00484-2","volume":"18","author":"E Jabbour","year":"2021","unstructured":"Jabbour E, Paul S, Kantarjian H. The clinical development of antibody\u2013drug conjugates\u2014lessons from leukaemia. Nat Rev Clin Oncol. 2021;18(7):418\u201333.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"4593_CR49","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","volume":"33","author":"D Bhojwani","year":"2019","unstructured":"Bhojwani D, et al. Inotuzumab Ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2019;33(4):884\u201392.","journal-title":"Leukemia"},{"issue":"9","key":"4593_CR50","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.21.01693","volume":"40","author":"MM O'Brien","year":"2022","unstructured":"O\u2019Brien MM, et al. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Protocol AALL1621. J Clin Oncol. 2022;40(9):956\u201367.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4593_CR51","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi L, et al. Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29(7):909\u201316.","journal-title":"J Clin Oncol"},{"issue":"279","key":"4593_CR52","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7(279):279ra40-279ra40.","journal-title":"Sci Transl Med"},{"issue":"12","key":"4593_CR53","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-11-0415","volume":"10","author":"J Chen","year":"2011","unstructured":"Chen J, et al. The Bcl-2\/Bcl-XL\/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011;10(12):2340\u20139.","journal-title":"Mol Cancer Ther"},{"key":"4593_CR54","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2019-126977","volume":"134","author":"NJ Lacayo","year":"2019","unstructured":"Lacayo NJ, et al. Safety and efficacy of venetoclax in combination with navitoclax in adult and pediatric relapsed\/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood. 2019;134:285.","journal-title":"Blood"},{"key":"4593_CR55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1182\/blood-2020-134582","volume":"136","author":"JE Rubnitz","year":"2020","unstructured":"Rubnitz JE, et al. Venetoclax and navitoclax in pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood. 2020;136:12\u20133.","journal-title":"Blood"},{"key":"4593_CR56","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1182\/blood-2018-99-113464","volume":"132","author":"T Alexander","year":"2018","unstructured":"Alexander T, et al. Venetoclax and navitoclax in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood. 2018;132:3966.","journal-title":"Blood"},{"issue":"12","key":"4593_CR57","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"W-S Huang","year":"2010","unstructured":"Huang W-S, et al. Discovery of 3-[2-(imidazo [1, 2-b] pyridazin-3-yl) ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl) phenyl} benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem. 2010;53(12):4701\u201319.","journal-title":"J Med Chem"},{"key":"4593_CR58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-134390","volume":"136","author":"NJ Short","year":"2020","unstructured":"Short NJ, et al. Interim results of the phase I\/II study of the ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2020;136:11\u20132.","journal-title":"Blood"},{"key":"4593_CR59","unstructured":"Agyemang PR. Profiling of FDA-Approved and clinical trial drugs revealed shared cytotoxicity and collateral sensitivity in resistant (H69AR) and Non-resistant (H69) small cell lung cancer cells.(Drug repurposing in cancer Chemotherapy). South Dakota State University; 2021."},{"key":"4593_CR60","doi-asserted-by":"crossref","unstructured":"Avendano C et al. Anticancer drugs targeting tubulin and microtubules. in Medicinal chemistry of anticancer drugs. 2008.","DOI":"10.1016\/B978-0-444-52824-7.00008-1"},{"issue":"1","key":"4593_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1568011023354290","volume":"2","author":"M Jordan","year":"2002","unstructured":"Jordan M. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chemistry-Anti-Cancer Agents. 2002;2(1):1\u201317.","journal-title":"Curr Med Chemistry-Anti-Cancer Agents"},{"issue":"3","key":"4593_CR62","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","volume":"71","author":"JA Silverman","year":"2013","unstructured":"Silverman JA, Deitcher SR. Marqibo\u00ae(vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71(3):555\u201364.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"22","key":"4593_CR63","doi-asserted-by":"publisher","first-page":"7167","DOI":"10.1158\/1078-0432.CCR-08-0169","volume":"14","author":"PG Morris","year":"2008","unstructured":"Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res. 2008;14(22):7167\u201372.","journal-title":"Clin Cancer Res"},{"key":"4593_CR64","volume-title":"Martindale: The Complete Drug Reference","author":"A Brayfield","year":"2014","unstructured":"Brayfield A. Martindale: The Complete Drug Reference. United Kingdom: Pharmaceutical Press; 2014."},{"issue":"17","key":"4593_CR65","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1182\/bloodadvances.2022007333","volume":"6","author":"IM Johnson","year":"2022","unstructured":"Johnson IM, et al. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood Adv. 2022;6(17):5227\u201331.","journal-title":"Blood Adv"},{"issue":"7","key":"4593_CR66","doi-asserted-by":"publisher","first-page":"E229","DOI":"10.1002\/ajh.26175","volume":"96","author":"NJ Short","year":"2021","unstructured":"Short NJ, et al. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021;96(7):E229.","journal-title":"Am J Hematol"},{"issue":"1","key":"4593_CR67","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-022-00621-9","volume":"12","author":"H Wang","year":"2022","unstructured":"Wang H, et al. Venetoclax-ponatinib for T315I\/compound-mutated Ph+ acute lymphoblastic leukemia. Blood Cancer J. 2022;12(1):20.","journal-title":"Blood Cancer J"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04593-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04593-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04593-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:03:19Z","timestamp":1776250999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04593-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4593"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04593-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"568"}}